LT3157531T - Žarnyno enteroendokrininės sistemos stimuliavimo būdai ir kompozicijos, skirtos su ja susijusioms ligoms arba būklėms gydyti - Google Patents

Žarnyno enteroendokrininės sistemos stimuliavimo būdai ir kompozicijos, skirtos su ja susijusioms ligoms arba būklėms gydyti

Info

Publication number
LT3157531T
LT3157531T LTEP15811714.3T LT15811714T LT3157531T LT 3157531 T LT3157531 T LT 3157531T LT 15811714 T LT15811714 T LT 15811714T LT 3157531 T LT3157531 T LT 3157531T
Authority
LT
Lithuania
Prior art keywords
stimulation
compositions
treatment
conditions
methods
Prior art date
Application number
LTEP15811714.3T
Other languages
English (en)
Lithuanian (lt)
Inventor
Michael Zasloff
Original Assignee
Enterin, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin, Inc. filed Critical Enterin, Inc.
Publication of LT3157531T publication Critical patent/LT3157531T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
LTEP15811714.3T 2014-06-23 2015-06-22 Žarnyno enteroendokrininės sistemos stimuliavimo būdai ir kompozicijos, skirtos su ja susijusioms ligoms arba būklėms gydyti LT3157531T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015657P 2014-06-23 2014-06-23
US14/329,627 US10040817B2 (en) 2013-10-03 2014-07-11 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
PCT/US2015/036935 WO2015200195A1 (en) 2014-06-23 2015-06-22 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Publications (1)

Publication Number Publication Date
LT3157531T true LT3157531T (lt) 2021-07-12

Family

ID=54869043

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15811714.3T LT3157531T (lt) 2014-06-23 2015-06-22 Žarnyno enteroendokrininės sistemos stimuliavimo būdai ir kompozicijos, skirtos su ja susijusioms ligoms arba būklėms gydyti

Country Status (19)

Country Link
US (10) US10040817B2 (enExample)
EP (1) EP3157531B1 (enExample)
JP (2) JP6692300B2 (enExample)
CN (2) CN113559108A (enExample)
BR (1) BR112016029917A2 (enExample)
CA (1) CA2951720C (enExample)
CY (1) CY1124554T1 (enExample)
DK (1) DK3157531T3 (enExample)
ES (1) ES2878077T3 (enExample)
HR (1) HRP20211005T1 (enExample)
HU (1) HUE054828T2 (enExample)
LT (1) LT3157531T (enExample)
MX (2) MX382442B (enExample)
PL (1) PL3157531T3 (enExample)
PT (1) PT3157531T (enExample)
RS (1) RS62064B1 (enExample)
SI (1) SI3157531T1 (enExample)
SM (1) SMT202100373T1 (enExample)
WO (1) WO2015200195A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
US20180344748A1 (en) * 2017-05-31 2018-12-06 Enterin Laboratories, Inc. Methods and compositions for preventing or treating chronic inflammatory diseases
US11083735B2 (en) * 2017-09-08 2021-08-10 Enterin, Inc. Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions
MA50536A (fr) 2017-10-30 2020-09-09 Enterin Inc Nouvelles formes solides de squalamine et procédés pour les produire
CN112312917A (zh) * 2018-03-27 2021-02-02 因特尔公司 用于治疗幻觉及其相关病症的方法和组合物
US20190381071A1 (en) * 2018-06-13 2019-12-19 Enterin, Inc. Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
EP3829587A4 (en) * 2018-08-03 2022-07-20 Enterin, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN AND GUESS DISORDERS
US20210315907A1 (en) * 2018-08-03 2021-10-14 Enterin, Inc, Compositions and methods for treating brain-gut disorders
EP3829537A4 (en) * 2018-08-03 2022-09-21 Enterin, Inc. LOW DOSAGE INTRANASAL DOSAGE FORMS OF AMINOSTEROL AND METHODS OF USE THEREOF
US20230125585A1 (en) * 2019-08-02 2023-04-27 Enterin, Inc. Dosing protocols and regimens for aminosterol treatment

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
US5352682A (en) 1993-03-08 1994-10-04 Digestive Care Inc. Compositions containing salts of bile acid-aminosalicylate conjugates
ATE169930T1 (de) 1993-03-10 1998-09-15 Magainin Pharma Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel
US5840740A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
WO1996008270A2 (en) 1994-09-13 1996-03-21 Magainin Pharmaceuticals Inc. Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds
US5834453A (en) 1995-05-30 1998-11-10 Lehigh University Methods for the manufacture and use of antimicrobial sterol conjugates
PT832094E (pt) * 1995-06-07 2004-06-30 Genaera Corp Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5840936A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US6143738A (en) 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5763430A (en) 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5874597A (en) 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5994336A (en) 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5795885A (en) 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5744453A (en) 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
DK0910382T3 (da) 1996-04-26 2003-10-06 Genaera Corp Squalamin i kombination med andre anticancermidler til behandling af tumorer
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
CA2255856C (en) 1996-05-17 2008-05-13 Magainin Pharmaceuticals Inc. Therapeutic uses for an aminosterol compound
AU5194998A (en) 1996-11-01 1998-05-29 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and uses therefor
EP1105407B1 (en) 1998-08-12 2007-10-10 Genaera Corporation Aminosterol compounds and uses thereof
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
US6900192B2 (en) 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
WO2002044324A2 (en) * 2000-10-06 2002-06-06 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
KR20150080013A (ko) * 2002-01-28 2015-07-08 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료용 조성물
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
CA2606077C (en) 2005-04-25 2013-07-09 Genaera Corporation Polymorphic and amorphous salt forms of squalamine dilactate
WO2009032321A2 (en) 2007-09-06 2009-03-12 Genaera Corporation A method for treating diabetes
US8247435B2 (en) * 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
US8623416B2 (en) 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
JP6165843B2 (ja) 2012-04-20 2017-07-19 オーエイチアール・ファーマシューティカル・インコーポレイテッドOhr Pharmaceutical,Inc. Ptp1b関連疾患の処置のためのアミノステロイド化合物
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
EP2934543B1 (en) 2012-12-20 2018-10-31 Mount Desert Island Biological Laboratory Stimulation and enhancement of regeneration of tissues
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Also Published As

Publication number Publication date
US10633413B2 (en) 2020-04-28
CY1124554T1 (el) 2022-07-22
DK3157531T3 (da) 2021-07-05
PL3157531T3 (pl) 2021-11-15
MX2016017368A (es) 2017-08-24
US20180319837A1 (en) 2018-11-08
US11440936B2 (en) 2022-09-13
SMT202100373T1 (it) 2021-07-12
US10208080B2 (en) 2019-02-19
EP3157531A1 (en) 2017-04-26
US10208079B2 (en) 2019-02-19
US10196420B2 (en) 2019-02-05
CA2951720A1 (en) 2015-12-30
MX2021005489A (es) 2021-06-18
US20150368290A1 (en) 2015-12-24
US10040817B2 (en) 2018-08-07
MX382442B (es) 2025-03-13
CN106535902A (zh) 2017-03-22
US10975116B2 (en) 2021-04-13
EP3157531B1 (en) 2021-03-31
BR112016029917A2 (pt) 2017-08-22
JP7010979B2 (ja) 2022-02-10
US20220220148A1 (en) 2022-07-14
SI3157531T1 (sl) 2021-09-30
JP2020097587A (ja) 2020-06-25
CA2951720C (en) 2023-09-26
WO2015200195A1 (en) 2015-12-30
HUE054828T2 (hu) 2021-10-28
HRP20211005T1 (hr) 2021-09-17
US20180002370A1 (en) 2018-01-04
CN113559108A (zh) 2021-10-29
US20190185513A1 (en) 2019-06-20
PT3157531T (pt) 2021-07-01
RS62064B1 (sr) 2021-07-30
US20190194243A1 (en) 2019-06-27
JP6692300B2 (ja) 2020-05-13
ES2878077T3 (es) 2021-11-18
EP3157531A4 (en) 2018-05-16
US20180327445A1 (en) 2018-11-15
JP2017519775A (ja) 2017-07-20
US20170327530A1 (en) 2017-11-16
CN106535902B (zh) 2021-05-25
US20170326156A1 (en) 2017-11-16
US20190194244A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
LT3157531T (lt) Žarnyno enteroendokrininės sistemos stimuliavimo būdai ir kompozicijos, skirtos su ja susijusioms ligoms arba būklėms gydyti
IL253945B (en) kdm1a inhibitors to treat the disease
EP3212233A4 (en) Combination therapy for treatment of disease
EP3263132C0 (en) Composition for treating il-6-related diseases
LT3206497T (lt) Kompozicijos ir būdai, skirti meibomo liaukos disfunkcijos gydymui
HUE058713T2 (hu) Kinolin-származékok gyulladásos megbetegedések kezelésére
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
SI3157534T1 (sl) Inhibitorji acetilholinesteraze za zdravljenje dermatoloških obolenj
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
PL3348273T3 (pl) Kompozycje na bazie ksyloglukanu i białek do leczenia zaburzeń jelitowych
LT3153511T (lt) 2-acilaminotiazolo dariniai, skirti panaudoti šlapimo pūslės/šlapimo takų ligų prevencijai arba gydymui
EP3253395C0 (en) PROBIOTIC PREPARATION FOR THE TREATMENT OF INTESTINAL INFLAMMATION
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
IL259381B (en) Mirabegron for the treatment of retinal diseases
IL252779A0 (en) Prevention and treatment of inflammatory conditions
HUE063820T2 (hu) Módszerek kardiovaszkuláris betegségek kezelésére
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases
GB201515244D0 (en) Treatment of inflammatory disease or condition
IL252707A0 (en) Compositions and methods for treating diseases and conditions
KR101583452B9 (ko) 위장질환 치료용 의약 조성물
EP3368512C0 (en) INDOLINE DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF FIBROTIC DISEASES